724 results about "Drug development" patented technology

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, perform computational fluid dynamics analysis, facilitate assessment of risk of heart disease and coronary artery disease, enhance drug development, determine a CAD risk factor goal, provide atherosclerosis and vascular morphology characterization, and determine indication of myocardial risk, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

An application method of a modified peptide derived from Urechis unicinctus is to prepare a drug for treating alcoholic liver disease. The modified peptide derived from Urechis unicinctus is one or more selected from F2-1: IHVKF (SEQ ID NO: 1), F2-2: VHFKI (SEQ ID NO: 2), F4-1: GAWKP (SEQ ID NO: 3), F4-2: AGWKP (SEQ ID NO: 4), F5-1: GTLKP (SEQ ID NO: 5), F5-2: GTPKL (SEQ ID NO: 6), F7-1: IIVRM (SEQ ID NO: 7), and F7-2: IRMVI (SEQ ID NO: 8). The modified peptide derived from Urechis unicinctus can enhance the degradation of alcohol and boost the survival rate of cells with alcoholic liver disease, and also alleviate lipid metabolism and inflammation in mice, protecting liver from alcoholic liver disease. When applied in drug development for treating alcoholic liver disease, the application method offers low-risk, low-cost, and is simple to operate therapeutic options.

The invention discloses a chemical reaction large language model training method and a synthetic path planning method, and belongs to the technical field of chemical information artificial intelligence. According to the method, a chemical reaction is expressed as a reaction sentence in an SMILES format, a digital sequence is generated by using a token taking atoms, punctuation marks, numbers and the like as units, and mask filling self-supervision pre-training is carried out by adopting a large language model based on a Transform architecture, so that a chemical reaction rule is learned. In combination with a Monte Carlo tree search algorithm, performing multi-step inverse synthesis path planning on the target molecule, and outputting strategy probability and value estimation; and through multi-task fine tuning, molecular property classification, reaction condition regression and process parameter complementation are supported. The method improves the chemical reaction modeling efficiency and the intelligent level of synthesis path planning, and is suitable for the fields of new drug research and development, material discovery and the like.

The invention discloses a computer-aided drug screening method, system or device based on FBXO2 and PKM2. The invention provides a brand-new method, system or equipment for screening oral squamous cell carcinoma treatment drugs based on FBXO2 and PKM2, provides a tool for new drug development and clinical application for treatment of oral squamous cell carcinoma, and has a wide application prospect.

The invention relates to the technical field of drug safety evaluation, in particular to a multi-center combined evaluation method and system for drug safety based on a graph neural network and federated learning. Known and unknown drug interaction is systematically predicted based on a drug multi-relation knowledge graph and a graph neural network, a key path of DDI is identified through a graph attention mechanism, a molecular mechanism of the interaction is revealed, and natural language interpretation is generated. And meanwhile, through privacy protection and multi-center cooperation, a federal learning architecture is utilized to break data islands and improve the external effectiveness of an evaluation conclusion on the premise of protecting patient privacy and meeting data compliance requirements. The heterogeneity of data of different mechanisms is effectively evaluated through distribution deviation detection, deviation caused by blind extrapolation is avoided, a real-world evidence methodology report and a data traceability auditing clue are automatically generated, the requirement of a supervision mechanism for real-world evidence quality is met, medicine supervision decision is supported, and medicine research, development and review are accelerated.

The present invention relates to an antibody or an antigen-binding fragment thereof binding to CLDN18.2, an antibody-drug conjugate comprising same, and a use of the antibody and the antibody-drug conjugate. An anti-CLDN18.2 monoclonal antibody according to the present invention comprises a fully human antibody sequence, thereby having low in vivo immunogenicity, and exhibits excellent antigen affinity and binding ability specific to a low expression to a high expression level of the CLDN18.2 protein. Thus, the antibody is expected to exhibit high specificity and safety as an antibody-based therapeutic agent such as in the form of a monoclonal antibody and / or an antigen-binding fragment (scFv), an antibody-drug conjugate (ADC), an immune cell engager, a chimeric antigen receptor (CAR), a multispecific antibody, and the like. In addition, the antibody according to the present invention may undergo cellular internalization, enables an anti-CLDN18.2 antibody-drug conjugate comprising said antibodies to be conveniently prepared, and has excellent yield and quality and thus is expected to be highly likely to be developed as a drug. A drug conjugate comprising the anti-CLDN18.2 antibody according to the present invention has excellent in vivo anticancer efficacy and has an expanded therapeutic index (TI) and thus is expected to be usefully employable for the treatment and / or prevention of cancer diseases expressing CLDN18.2 and related diseases.

The invention discloses a fungal effect protein prediction model based on a protein language model and deep learning, and relates to the technical field of bioinformatics and deep learning, and the method comprises the steps: 1, collecting fungal effect protein data and non-effect protein data; 2, obtaining protein embedding through a protein language model; 3, performing oversampling processing on the data; 4, constructing a deep learning model; 5, model training; and 6, performing cross validation and independent test evaluation. According to the invention, a geometric oversampling technology (G-SMOTE) is adopted to carry out oversampling processing, so that the problem of sample imbalance is solved; a protein language model is adopted to obtain protein embedding characteristics to strengthen protein expression; and the prediction accuracy is improved by using a deep learning model architecture. The method can be applied to agricultural disease prevention and control, drug development and biotechnology research, important support is provided for identification and research of fungal effect protein, prediction accuracy can be improved, dependence on expensive experiments is reduced, and labor cost is reduced.

The invention relates to the technical field of disease animal models, in particular to a construction method, an evaluation method and application of a bipolar affective disorder liver stagnation and spleen deficiency syndrome combined animal model. According to the method, a liver depression and spleen deficiency syndrome modeling method is adopted for model construction, evaluation indexes are formulated by combining manic and depression behavior expressions of mice and innovatively combining typical expressions of liver depression and spleen deficiency, a liver depression and spleen deficiency syndrome animal model evaluation method is explored, and a thought is provided for achieving standardization and normalization of liver depression and spleen deficiency syndrome model evaluation. The modeling method is simple and economical, provides an experimental animal model for syndrome differentiation treatment of diseases, particularly provides a corresponding animal model for traditional Chinese medicine syndrome differentiation treatment and new drug pharmacological experiments, accelerates the progress of traditional Chinese medicine disease syndrome research and new drug development, provides technical service for drug evaluation, and has great application value.

The invention discloses bifidobacterium longum B14 with efficient lactose degradation capability and low gas production characteristic and application of the bifidobacterium longum B14, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium longum B14 is GDMCC No: 67276. The bifidobacterium longum B14 strain provided by the invention can effectively decompose lactose in intestinal tracts, meanwhile, uncomfortable symptoms such as abdominal distension caused by gas production are reduced to the maximum extent, and the technical problem that in the prior art, an efficient lactose degradation strain and the low gas production characteristic are difficult to consider at the same time is successfully solved. The invention provides a core strain resource for developing probiotic products capable of relieving main symptoms of lactose intolerance and remarkably reducing side effects. The strain has a definite application prospect and a remarkable industrial value in development of health care products and medicines.

The invention discloses a degradation agent based on indole group fusion covalent warheads and a preparation method and application thereof, and relates to the technical field of drug development, the structural formula of the degradation agent is as follows: R is a single bond or-NH-; a single bond, a, a, a, or a; and is-NH-, or; or; r1 and R2 are respectively and independently-H,-F,-Cl,-Br,-CH3,-OCH3,-NO2,-CH2-O-Ph or-CN; ph is phenyl; and a connection site is represented. According to the invention, an E3 ubiquitin ligase ligand is constructed by using an indole skeleton and acrylate, and then the E3 ubiquitin ligase ligand is connected with a BRD4 protein inhibitor JQ1 through a linker, so that a series of degradation agents based on indole group fusion covalent warheads are obtained, and targeted degradation of BRD4 protein is realized while an E3 ubiquitin ligase ligand library and a protein degradation targeted chimera molecular library are enriched.

The present invention discloses a method for preparing a peptide compound with CCK receptor agonistic and / or antagonistic activity. The method uses a sequence of solution-phase reactions to generate high-purity and scalable product without chromatographic purification, suitable for industrial production and pharmaceutical development.

The invention relates to the technical field of biological medicines, in particular to a polycyclic polyisopentenyl cyclopentanone compound as well as a preparation method and application thereof. The polycyclic polyisopentenyl cyclopentanone compound provided by the invention has a structural formula as shown in a formula 1; the preparation method comprises the following steps: by taking dry fruits of hypericum berry as raw materials, carrying out percolation extraction and concentration to obtain an extract, suspending the extract in water to obtain a suspension, and extracting and concentrating the suspension with petroleum ether to obtain a crude extract; the crude extract is taken and subjected to positive and negative phase silica gel column separation, MCI medium-pressure column chromatography, Sephadex LH-20 gel column chromatographic separation, high performance liquid chromatography preparation and CHIRALPAK IG chiral column resolution, and the polycyclic polyisopentenyl cyclopentanone compound is obtained. The protection activity of the compound on AC16 myocardial cell injury induced by cold ischemia is evaluated, and the compound can be used for preparing the polycyclic polyisopentenyl cyclopentanone compound. The compounds can be used as lead compounds for developing medicines for preventing and treating myocardial cold ischemia injury.

This document relates to crystalline or amorphous forms of oxoisoindole-5-carboxamide compounds, or salts or solvates thereof. It also discloses compositions containing the crystalline or amorphous forms, as well as methods for preparing and using the crystalline or amorphous forms. The resulting crystalline or amorphous forms have excellent solid-state stability and are of great value in drug development, formulation development, and production.

The invention relates to the field of biological medicine, and provides application of a biheterocyclic derivative in treating breast cancer and serving as an antitumor drug sensitizer. The invention discloses application of a biheterocyclic derivative in inhibiting proliferation of breast cancer cells, inhibiting formation, growth and metastasis of breast cancer tumors and enhancing chemosensitivity of the breast cancer cells and the tumors. It is found for the first time that the compound can inhibit proliferation of breast cancer cells at low concentration without affecting normal cells, and chemosensitivity of the breast cancer cells is improved. The formation and growth of breast cancer tumors can be obviously inhibited at the concentration without obvious organ toxicity, and the chemosensitivity of the breast cancer tumors is enhanced. According to the invention, the anticancer activity and the chemotherapy sensitization effect of the compound can be clarified, and a pharmaceutical basis is provided for drug development in the field of breast cancer treatment.

The invention discloses a degradation agent based on benzimidazole fused covalent warheads as well as a preparation method and application of the degradation agent, and relates to the technical field of drug development. The structural formula of the degradation agent based on the benzimidazole fused covalent warhead is shown in the specification, wherein, is phenyl or substituted phenyl; r is methyl or tertiary butyl; the structure is selected from one of the following structures:,,,,,,,,, and; and a connection site is represented. According to the invention, a series of degradation agents based on benzimidazole fused covalent warheads are obtained by utilizing the modular design of a benzimidazole guiding group and an acrylate covalent warhead and then connecting with a BRD4 protein inhibitor JQ1 through a connexon. The degradation agent based on the benzimidazole fused covalent warhead can target the BRD4 protein and efficiently degrade the BRD4 protein. Therefore, targeted degradation of the BRD4 protein is realized while a protein degradation targeted chimera molecular library is enriched.

Provided in the present invention is an anhydrous crystal form CH of resmetirom. The preparation process of the crystal form is simple, and is easy and convenient to operate. The new crystal form has good stability, is easy to store during the production and circulation process, has a stable quality when used for preparing a tablet formulation, and has a certain advantage in dissolution rate compared with the original crystal form, thereby providing a good selection for the preparation of a pharmaceutical formulation thereof, and having a very important significance on drug development.

The invention relates to a construction method of an atopic dermatitis mouse model. The method sequentially comprises the following steps: screening mice, feeding the mice in an SPF (specific pathogen free)-level animal house by adopting an illumination and darkness alternating period, and freely taking standard feed and drinking water; after the animals adapt to the environment, the animals are divided into a model group and a control group, and the control group is only subjected to first sensitization treatment; the model group is subjected to first-time sensitization treatment and maintenance treatment, the interval between the first-time sensitization treatment and the maintenance treatment is 4 days, and the maintenance treatment is performed for three times per week and is totally 16 days continuously. According to the method disclosed by the invention, the mouse model which is highly similar to human atopic dermatitis in immunology, pathology and molecular level is successfully established, the limitations of poor repeatability, incomplete pathological characteristics, single immunoreaction type and the like of the existing model are overcome, and an effective experimental platform is provided for disease research and new drug development.

The invention discloses a chain dienol carboxylate compound and a preparation method thereof, alkynyl allyl ester is used as a substrate, in the presence of a nucleophilic catalyst, alkynyl allyl ester, a carboxylic acid compound and an active methylene compound are subjected to a biaddition reaction, and a product containing a chain dienol carboxylate structure is obtained with high double bond cis-trans selectivity. The compound with the chain diene carboxylic ester structure is a chain compound with alternating single and double bonds, and has obvious and important application value in the fields of medicinal chemistry, analytical chemistry, synthetic chemistry and the like. The compound containing the chain-like dialkenyl carboxylic ester structure is a dienol ester compound, and has extremely wide and important application value in many fields such as choline active drug development, fluorescence detection and diagnosis molecular research, natural product synthesis and the like; according to the invention, an efficient synthesis means and a series of candidate compounds for further development can be provided for the development of diene alcohol ester functional molecules with high similarity.

The invention relates to the technical field of gene therapy and drug development, and provides application of a UCH37 inhibitor in preparation of a drug for treating osteoporosis. The expression level of UCH37 in blood of osteoporosis patients is obviously higher than that of UCH37 in blood of healthy people, and the UCH37 is in positive correlation with osteoclast active markers such as NFATC1 and MMP9. The UCH37 inhibitor is applied to preparation of the medicine for treating osteoporosis and directly targets UCH37, the curative effect does not depend on the expression change of ADRM1, no matter the ADRM1 of osteoporosis patients is in a low or high expression state, an osteoclast activation pathway can be stably blocked, the consistency of treatment effects of different individuals is ensured, the range of applicable people of the medicine is expanded, and the application prospect is broad. The compound has the characteristics of clear action mechanism and wide application range, and provides important theoretical basis and conversion prospect for developing novel and efficient medicines for treating osteoporosis.

The invention discloses a 2-amino-4-(5-cyano-1-isopropyl-1H-indole-3-yl) pyrimidine compound and application thereof, the compound has the following structural general formula: in the formula, substituent R is substituted phenyl, the number of substituent groups on the benzene ring of the substituted phenyl is 1-2, and the substituent groups on the benzene ring of the substituted phenyl are 1-2. Substituent groups are respectively and independently selected from nitro, cyano, halogen, carbamoyl, furyl or pyridyl. The 2-amino-4-(5-cyano-1-isopropyl-1H-indole-3-yl) pyrimidine compound designed and synthesized by the invention is a novel efficient NF-kappa B induced kinase (NIK) inhibitor, and is suitable for drug development taking NF-kappa B induced kinase (NIK) as a target spot, and the obtained drug can be used for treating malignant tumors such as leukemia, multiple myeloma and the like.

The application discloses a covalent polypeptide inhibitor targeting protein kinase A, a conjugate, a kit, a pharmaceutical composition and application. The general formula of the covalent polypeptide inhibitor is Z1-Seq-Z2; wherein Seq is an amino acid sequence; the C-terminal of Seq comprises a pseudo-substrate recognition motif recognized by protein kinase A, a non-natural amino acid with a covalent reaction group, and can be covalently crosslinked with a Cys200 residue on a catalytic subunit of protein kinase A; Z1 is selected from hydrogen, an acyl group, a fluorescent group, biotin, an isotopic tag or a biological ortho-reaction group; and Z2 is selected from a hydroxyl group, an amino group, a cell-penetrating peptide or a stabilization modification group. The covalent polypeptide inhibitor can strongly and irreversibly inhibit PKA activity, and can be used as an active probe to specifically label active PKA in a complex biological sample, and is used for biological research and drug development.

This invention relates to the application of β-sitosterol glycoside in the preparation of products for treating lung cancer. This invention creatively provides a new use for the active monomer β-sitosterol glycoside, demonstrating that β-sitosterol glycoside can significantly inhibit the migration ability of lung cancer cells at doses without cell proliferation inhibitors, clarifying the specificity of its anti-metastatic effect, and laying the foundation for further new drug development of this monomer component. Through an in vivo mouse lung metastasis model, this invention demonstrates that β-sitosterol glycoside effectively inhibits the formation of lung metastases while exhibiting no significant toxic side effects in experimental animals, demonstrating high safety, and providing a new candidate molecule for the development of low-toxicity, highly effective anti-lung cancer metastasis drugs.

The invention relates to a method for rapidly preparing vernonia anthelmintica dealicin from vernonia anthelmintica dealicin, which comprises the following steps: carrying out ultrasonic extraction by using ethanol, enriching by using macroporous resin to obtain a vernonia anthelmintica dealicin extract, and carrying out extraction and pilot plant test preparative liquid chromatography separation to obtain a high-purity vernonia anthelmintica dealicin compound. The results of subsequent researches show that the vernonia anthelmintica dealicin can significantly inhibit the secretion of the chemotactic factor, and the inhibition rate of 1mol / L of vernonia anthelmintica dealicin on the release level of the chemotactic factor CXCL10 reaches 75.83%. The vernonia anthelmintica macrobrachin reduces the recruitment of self-reactive T cells to the skin by blocking a CXCL10-mediated inflammation signal channel, so that melanocytes are protected, and pigment regeneration is promoted. Therefore, the vernonia anthelmintica macrobrachin inhibits the secretion of the chemotactic factor CXCL10 in a targeted manner, can be used as a potential effective monomeric compound in the development of vitiligo medicines for research, and is expected to become a new strategy for treating vitiligo.

The application discloses a marine source penicillium and a fermentation method and application thereof. The marine source penicillium is named Penicillium sp. DSF059, and the preservation number is CCTCC NO: M 20232310. Penicilliu The application optimizes the culture condition of the strain, selects a culture medium and culture condition with high yield of antibacterial active compounds to carry out fermentation, so that more target products can be obtained, the operation is simple, the cost is low, and meanwhile, the marine source penicillium Penicilliu Penicillium sp. DSF059 can provide an excellent strain for new drug development of resisting plant pathogenic fungi such as coffee leaf blight, coffee brown spot disease, grape gray mold disease, Chinese cinnamon brown spot disease, citrus black rot disease, pepper late blight, hickory leaf blight, coffee black spot disease and four pathogenic fungi separated from coffee leaf diseases and Staphylococcus aureus, and has a good application prospect for preventing and treating the plant pathogenic fungi and Staphylococcus aureus.

Provided are small-fragment RNA derived from a circular RNA and the use thereof in the treatment of diabetic vascular diseases. The nucleotide sequence of the small-fragment RNA is CUAGCCGAAUGUUAAAAAAU. The provided small-fragment RNA has the effects of well protecting and maintaining the biological functions of vascular endothelial cells, has good structural stability, has a long half-life in vivo, and has the advantages of low effective concentration, high biological safety, etc. The provided small-fragment RNA has good application potentials in the field of clinical nucleic acid drug development, and provides a new idea for the treatment of chronic progressive vascular lesions caused by diabetes.

This invention provides a non-cytotoxic, in vivo compatible proximity labeling method for peroxidases, Hi-APEX, and its applications, belonging to the field of biotechnology. This invention provides a method for labeling interacting proteins, neighboring proteins, and / or neighboring RNA. By introducing TP probes, it completely overcomes the core limitation of peroxidase dependence on H2O2 without sacrificing the original high spatiotemporal resolution. The method provided by this invention exhibits significantly superior technical effects compared to existing technologies in terms of reduced toxicity, enabling in vivo application, precise analysis of redox-sensitive processes, dynamic tracking of protein transport, and simultaneous spatial multi-omics analysis. It provides a powerful tool for life science research and drug development, possessing significant scientific value and broad application prospects.

The application provides an islet-vascular co-culture system based on a microfluidic chip, a building method and application, and the building method of the islet-vascular co-culture system comprises the following steps: S1, preparing microfibers loaded with islets; S2, preparing an assembled chip, the assembled chip comprises a containing cavity, first microchannel networks and second microchannel networks are symmetrically arranged on two sides of the containing cavity, and the first microchannel networks and the second microchannel networks are respectively communicated with a liquid inlet and a liquid outlet at an end away from the containing cavity; S3, controlling the flow of the liquid inlet to be 6-8 muL / min to carry out dynamic culture. The application can simulate the key structure and characteristics of islet tissue, can evaluate a diabetes treatment drug in vitro, can bridge the gap between in vitro and in vivo models, and can provide new tools and methods for the fields of drug development, disease model construction and personalized medical treatment.

The invention belongs to the technical field of crystal form drug molecules, and particularly relates to a baricitinib-trimesic acid eutectic crystal and a preparation method thereof. The baricitinib-trimesic acid eutectic crystal provided by the invention is good in stability and high in solubility, and has improved pharmacokinetics, so that subsequent development requirements of drugs are met; the preparation method is simple to operate, easy to control the crystallization process, good in reproducibility and suitable for industrial production.

The application belongs to the field of chemical medicines, and particularly relates to a quinoline compound, a preparation method and use thereof and a pharmaceutical composition thereof. The application provides a quinoline compound shown in formula I, which has excellent DNA methyltransferase 1 (DNMT1) inhibitory activity and good selectivity, can be used as a novel DNMT1 inhibitor, and provides a new option for drug development and application of diseases driven by DNMT1. Formula I.

The application discloses a kind of miraculin compounds and its extraction method and application, belong to the field of traditional Chinese medicine extraction, specifically related to a kind of miraculin compounds as shown in general formula (I) and (II) isolated from Rhododendron dauricum and the extraction method of the compound, and the compound or the isomer of the compound, or the inhibitory effect of the compound on inflammation in pharmaceutically acceptable salt or pharmaceutical composition comprising the compound can be used for preparing anti-inflammatory drugs.The application further enriches the structural diversity of active substances of Rhododendron dauricum, which lays a foundation for subsequent related biological activity tests of monomeric compounds, provides active lead compounds for new drug development, and also provides a theoretical basis for in-depth research and development of Rhododendron dauricum medicinal materials.